Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/139109
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Evaluation of patient and physician assessments of gastrointestinal disease activity in systemic sclerosis |
Author: | Ross, L. Proudman, S. Walker, J. Stevens, W. Ferdowsi, N. Quinlivan, A. Morrisroe, K. Baron, M. Nikpour, M. |
Citation: | Journal of Rheumatology, 2022; 50(4):519-525 |
Publisher: | The Journal of Rheumatology |
Issue Date: | 2022 |
ISSN: | 0315-162X 1499-2752 |
Statement of Responsibility: | Laura Ross, Susanna Proudman, Jennifer Walker, Wendy Stevens, Nava Ferdowsi, Alannah Quinlivan, Kathleen Morrisroe, Murray Baron, and Mandana Nikpour |
Abstract: | Objective: To assess whether patient and physician global assessment of gastrointestinal tract (GIT) disease in systemic sclerosis (SSc) are associated with a meaningful change in disease status. Methods: One hundred forty-three participants from the Australian Scleroderma Cohort Study were recruited to this study. Using logistic regression analysis, we evaluated the relationship between patient-reported and physician-assessed GIT disease status and symptoms, measures of health-related quality of life (36-item Short Form Health Survey [SF-36]) and GIT disease severity, measured by the Scleroderma Clinical Trials Consortium UCLA Gastrointestinal Tract 2.0 (GIT 2.0) score. Results: Patient-reported worsening of GIT symptoms in the month preceding assessment was significantly associated with more severe GIT disease (odds ratio [OR] 6.14, P < 0.01) and progressive worsening GIT disease severity as measured by the GIT 2.0 score (OR 45.98, P < 0.01). The new onset of reflux was the only specific symptom associated with patient-reported GIT disease activity (OR 2.98, P = 0.04). Physicianassessed GIT disease activity was not significantly associated with higher GIT 2.0 scores or increasing severity of disease. Patient-reported and physician-assessed GIT activity was not associated with SF-36 scores. Conclusion: In the absence of objective measures of GIT disease activity in SSc, patient-reported symptoms of GIT disease could be used to indicate disease activity and should merit consideration for inclusion in a multisystem disease activity index. |
Keywords: | systemic sclerosis; gastrointestinal; disease activity; patient-reported outcomes |
Rights: | © 2023 The Journal of Rheumatology. |
DOI: | 10.3899/jrheum.220832 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/GNT1176538 |
Published version: | http://dx.doi.org/10.3899/jrheum.220832 |
Appears in Collections: | Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.